Novel HMG-CoA reductase inhibitors

Claim 1

A compound represented by the following structural formula (I): ##STR8## wherein: R 1 is selected from: (1) C 1-10 alkyl; (2) substituted C 1-10 alkyl in which one or more substituent(s) is selected from (a) halogen, (b) hydroxy, (c) C 1-10 alkoxy, (d) C 1-5 alkoxycarbonyl, (e) C 1-5 acyloxy, (f) C 3-8 cycloalkyl, (g) phenyl, (h) substituted phenyl in which the substituents are X and Y, (i) C 1-10 alkylS(O) n in which n is 0 to 2, (j) C 3-8 cycloalkylS(O) n , (k) phenylS(O) n , (l) substituted phenylS(O) n in which the substituents are X and Y, and (m) oxo; (3) C 1-10 alkoxy; (4) C 2-10 alkenyl; (5) C 3-8 cycloalkyl; (6) substituted C 3 ∝8 cycloalkyl in which one substituent is selected from (a) C 1-10 alkyl (b) substituted C 1-10 alkyl in which the substituent is selected from (i) halogen, (ii) hydroxy, (iii) C 1-10 alkoxy, (iv) C 1-5 alkoxycarbonyl, (v) C 1-5 acyloxy, (vi) phenyl, (vii) substituted phenyl in which the substituents are X and Y, (viii) C 1-10 alkylS(O) n , (ix) C 3-8 cycloalkylS(O) n , (x) phenylS(O) n , (xi) substituted phenylC(O) n in which the substituents are X and Y, and (xii) oxo, (c) C 1-10 alkylS(O) n , (d) C 3-8 cycloalkylS(O) n , (e) phenylS(O) n , (f) substituted phenylS(O) n in which the substituents are X and Y, (g) halogen, (h) hydroxy, (i) C 1-10 alkoxy, (j) C 1-5 alkoxycarbonyl, (k) C 1-5 acyloxy, (l) phenyl, and (m) substituted phenyl in which the substituents are X and Y; (7) phenyl; (8) substituted phenyl in which the substituents are X and Y; (9) amino; (10) C 1-5 alkylamino; (11) di(C 1-5 alkyl)amino; (12) phenylamino; (13) substituted phenylamino in which the substituents are X and Y; (14) phenyl C 1-10 alkylamino; (15) Substituted phenyl C 1-10 alkylamino in which the substituents are X and Y; and (16) a member selected from (a) C 1-10 alkyl, (b) phenyl, and (c) substituted phenyl in which the substituents are X and Y; R 2 and R 3 are independently selected from: (1) hydrogen; (2) C 1-10 alkyl; (3) substituted C 1-10 alkyl in which one or more substituent(s) is selected from (a) halogen, (b) hydroxy, (c) C 1-10 alkoxy, (d) C 1-5 alkoxycarbonyl, (e) C 1-5 acyloxy, (f) C 3-8 cycloalkyl, (g) phenyl, (h) substituted phenyl in which the substituents are X and Y, and (i) oxo; (4) C 1-10 acyl; (5) substituted C 1-10 acyl in which one or more substituent(s) is selected from (a) halogen, (b) hydroxy, (c) C 1-10 alkoxy, (d) C 1-5 alkoxycarbonyl, (e) C 1-5 acyloxy, (f) C 3-8 cycloalkyl, (g) phenyl, (h) substituted phenyl in which the substituents are X and Y, and (i) oxo; (6) phenylcarbonyl; (7) substituted phenylcarbonyl in which the substituents are X and Y; (8) C 1-5 alkylaminocarbonyl; (9) di(C 1-5 alkyl)aminocarbonyl; (10) phenylaminocarbonyl; (10) substituted phenylaminocarbonyl in which the substituents are X and Y; (11) phenyl C 1-10 alkylaminocarbonyl; (12) substituted phenyl C 1-10 alkylaminocarbonyl in which the substituents are X and Y; R 4 is selected from: trifluoromethyl, C 1-3 alkyl, nitro, cyano or group selected from: (1) R 8 O (CH 2 ) in which m is 0 to 3 and R 8 and hydrogen, C 1-3 alkyl or hydroxy-C 2-3 alkyl; (2) ##STR9## in which R 9 is hydrogen, C 1-3 alkyl, hydroxy-C 2-3 alkyl, phenyl, naphthyl, amino-C 1-3 alkyl, C 1-3 alkylamino-C 1-3 alkyl, di(C 1-3 alkyl)amino-C 1-3 alkyl hydroxy-C 2-3 alkylamino-C 1-3 alkyl or di(hydroxy-C 2-3 alkyl) amino-C 1-3 alkyl; (3) ##STR10## in which R 10 is hydrogen, C 1-3 alkyl, hydroxy-C 2-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, phenyl or naphthyl; ##STR11## in which R 11 and R 12 independently are hydrogen, C 1-3 alkyl or, hydroxy-C 2-3 alkyl (5) R 13 S(O) n (CH 2 ) m in which R 13 is hydrogen, C 1-3 alkyl, amino, C 1-3 alkylamino or di(C 1-3 alkyl)amino; and a, b, c and d each represent single bonds or one of a, b, c and d represents a double bond or both a and c or b and d represent double bonds; or a pharmaceutically acceptable salt thereof.